Company Overview
Company Type: Private Company
Website: www.zucara.ca
Number of Employees: -
Year Founded: 2014
Total Amount Raised (CAD mm)†: 36.29
Total Rounds of Funding**:4
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Zucara Therapeutics Inc. develops drug therapy that prevents hypoglycemia in patients with diabetes. The company is engaged in developing treatments to prevent low blood sugar that blocks somatostatin type 2 receptors. Zucara Therapeutics Inc. was incorporated in 2014 and is based in Toronto, Canada with an additional office in Vancouver, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Midmer, Michael
CEO & President
Liggins, Richard
Chief Scientific Officer

Key Board Members
Name
Title
Riddell, Michael 
Chair of Clinical & Scientific Advisory Board
Frier, Brian 
Member of Clinical Advisory Board
Piché, Claude A.
Director
Seaquist, Elizabeth R.
Member of Clinical Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
1300-661 University Avenue Fourth Floor | Toronto, ON | M5G 0B7 | Canada

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Juvenile Diabetes Research Foundation International Inc.
Jun-15-2023
Minority
-
Growth
Perceptive Advisors LLC
Mar-31-2020
Minority
-
Series A
Accel-Rx
Nov-03-2016
Minority
-
Venture
Centre for Drug Research and Development
Nov-03-2016
Minority
-
Venture
MaRS Innovation Inc.
Nov-03-2016
Minority
-
Venture


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jun-15-2023
Jun-15-2023
Private Placement
Target
Zucara Therapeutics Inc.
Juvenile Diabetes Research Foundation International Inc.

2.00
Mar-31-2020
Mar-31-2020
Private Placement
Target
Zucara Therapeutics Inc.
Perceptive Advisors LLC Buyer Funds:Perceptive Xontogeny Venture Fund, LP

21.00
Apr-09-2018
Apr-09-2018
Private Placement
Target
Zucara Therapeutics Inc.


3.90
Nov-03-2016
Nov-03-2016
Private Placement
Target
Zucara Therapeutics Inc.
Accel-Rx,Centre for Drug Research and Development,MaRS Innovation Inc.

0.53
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-25-2023
Product-Related Announcements
Zucara Therapeutics Inc. Doses First Patient in Phase 2a 'ZONE' Trial
Sep-20-2023
Company Conference Presentations
Zucara Therapeutics Inc. Presents at Annual Boulder Peptide Symposium, Sep-20-2023 09:30 AM
Sep-13-2023
Company Conference Presentations
Zucara Therapeutics Inc. Presents at BioPharm America 2023, Sep-13-2023
Jun-15-2023
Regulatory Authority – Compliance
Zucara Therapeutics Announces Additional Funding from JDRF to Support ZT-01 Phase 2 Study
Jun-15-2023
Private Placements
Zucara Therapeutics Inc. announced that it has received $2 million in funding from Juvenile Diabetes Research Foundation International Inc.


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 09:18 PM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc
Reports
48
GlobalData

Jun 16, 2023 07:49 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc
Reports
47
GlobalData

Mar 16, 2023 04:59 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc
Reports
47
GlobalData

Dec 13, 2022 12:18 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc
Reports
53
GlobalData

Nov 15, 2022 02:46 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
22
GlobalData

Sep 19, 2022 05:25 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc
Reports
52
GlobalData

Jul 27, 2022 05:59 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
22
GlobalData

Jun 15, 2022 04:00 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc
Reports
51
GlobalData

May 18, 2022 02:49 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
22
GlobalData

Mar 11, 2022 03:04 AM
Zucara Therapeutics Inc.
Zucara Therapeutics Inc
Reports
50


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Oct-17-2023
Conferences
Oct-18-2023 1:15 PM (PST)
Company Conference Presentations
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Riddell, Michael 
Chair of Clinical & Scientific Advisory Board
-
-

Frier, Brian 
Member of Clinical Advisory Board
-
-

Piché, Claude A.
Director
-
-

Seaquist, Elizabeth R.
Member of Clinical Advisory Board
-
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Midmer, Michael
CEO & President
-
-
-
Liggins, Richard
Chief Scientific Officer
-
-
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
